

CURRICULUM VITAE

Apr. 2022

DONG-YEOP SHIN, M.D.,Ph.D.

Assignments

Associate Professor,

Division of Hematology and Medical Oncology, Department of Internal Medicine,
Seoul National University Hospital,

Mailing Address

101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

Tel) 82-2-2072-7209 / 82-10-8631-5510

Fax) 82-2-2072-7379

E-mail) shindongyeop@snu.ac.kr; shindongyeop@snuh.org; stephano.dyshin@gmail.com

Academic background

2012 ~ 2015 Doctor of Philosophy (Molecular Oncology), Graduate School,
Seoul National University, Seoul, Korea

(Thesis: The role of histone deacetylase inhibitor romidepsin in EBV-positive diffuse
large B-cell lymphoma)

2009 ~ 2011 Master of Science, Graduate School, Seoul National University, Seoul, Korea

2002 ~ 2006 College of Medicine, Seoul National University, Seoul, Korea

Career

2020 - present Associate Professor, Division of Hematology & Medical Oncology,
Department of Internal Medicine, Seoul National University Hospital.

2019 - 2020 Visiting Scholar, Hal Broxmeyer lab, Department of Microbiology and Immunology,
Indiana University School of Medicine, IN, U.S.

2016 ~ 2020 Assistant Professor, Division of Hematology & Medical Oncology,
Department of Internal Medicine, Seoul National University Hospital.

2012 ~ 2016 Staff Physician, Division of Hematology & Medical Oncology,
Department of Internal Medicine, Korea Cancer Center Hospital

2011 ~ 2012 Clinical Fellowship, Department of Hematology and Medical Oncology,
Seoul National University Hospital

2006 ~ 2011 Internship/Residency, Internal Medicine, Seoul National University Hospital

Qualifications

2006 Korean Medical License (No. 90017)

2011 Korean Board Certificate in Internal Medicine (No. 12955)

2013 Subspecialty Board Certified, Hemato-Oncology (No.6-13-461)

Professional Affiliation

Korean Society of Hematology (KSH)

Korean Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party (AML/MDS WP)

Korean Multiple Myeloma Working Party (KMMWP)

Korean Society of Blood and Marrow Transplant (KSBMT)

Korean Society of Medical Oncology (KSMO)

Korean Cancer Association

Honors and Awards

2018 Best Oral Presentation Award (2nd International Congress of BMT, Busan, Korea)

2016 Young Investigator Award (14th Congress of Korean Association of Clinical Oncology, Seoul, Korea)

2015 Travel Grant (ESMO Asia 2015, Singapore)

2014 Korea Cancer Foundation - Chong Kun Dang Academy Award (12th Congress of Korean Association of Clinical Oncology, Seoul, Korea)

2010 Best Poster Presentation Award (15th Congress of Asia-Pacific Blood and Marrow Transplantation, Phuket, Thailand)

2010 Hanmi Best Oral Presentation Award (3th Congress of Korean Association of Clinical Oncology, Seoul, Korea)

Research Interests

Acute Myeloid Leukemia/Acute Lymphoid leukemia – Leukemic Stem Cell

Hematopoietic Stem/Progenitor Cell

Allogeneic Hematopoietic Stem Cell Transplantation

Aplastic anemia/Thrombocytopenia/Megakaryopoiesis

Publications

First or Corresponding author only

1. **Shin DY**, Lee YG, Lee HJ, Choi S, Park JJ, Kim DW. Long-term disease-free survival of patients with primary cardiac lymphoma treated with systemic chemotherapy and radiotherapy. Korean J Hematol. 2010 Dec;45(4):282-5

2. **Shin DY**, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study. Cancer Chemother Pharmacol. 2011 Jul;68(1):165-75

3. **Shin DY**, Jeon YK, Hong YS, Kim TM, Lee SH, Kim DW, Kim I, Yoon SS, Heo DS, Park S, Kim BK. Clinical dissection of multicentric Castleman disease. *Leuk Lymphoma*. 2011 Aug;52(8):1577-22
4. **Shin DY**, Kim I, Kim KH, Choi Y, Beom SH, Yang Y, Lim Y, Lee E, Lee JK, Kim JY, Kim HK, Yoon SS, Lee DS, Park S, Kim BK. Acute lymphoblastic leukemia in elderly patients: a single institution's experience. *Korean J Intern Med*. 2011 Sep;26(3):328-39
5. Cho HJ, **Shin DY**, Kim JH, Bae JY, Lee KH, See CJ, Kim N, Park EK, Ra EK, Lee JE, Hong YC, Kim HK, Park SS, Yoon SS, Lee DS, Han KS, Park MH, Park S, Kim BK, Kim I. Impact of vitamin D receptor gene polymorphisms on clinical outcomes of HLA-matched sibling hematopoietic stem cell transplantation. *Clin Transpl*. 2011 May-Jun;26(3):476-83 (Co-1st author)
6. **Shin DY**, Lee JO, Kim YJ, Park MS, Lee KW, Kim KI, Bang SM, Lee JS, Kim CH, Kim JH. Toxicities and functional consequences of systemic chemotherapy in elderly Korean patients with cancer: A prospective cohort study using Comprehensive Geriatric Assessment. *Journal of Geriatr Oncol*. 2012 Oct;3(4):359-367
7. Kim SY, **Shin DY**, Lee SS, Suh C, Kwak JY, Kim HG, Lee JH, Lee SI, Lee YR, Kang SH, Mun SK, Lee MJ, Lee HR, Yang SH, Kang HJ. Clinical characteristics and outcomes of primary bone lymphoma in Korea. *Korean J Hematol* 2012 Sep;47(3):213-8 (Co-1st author)
8. **Shin DY**, Kim I, Kim JH, Lee YG, Kang EJ, Cho HJ, Lee KH, Kim HJ, Park EH, Lee JE, Bae JY, See CJ, Yoon SS, Park SS, Han KS, Park MH, Hong YC, Park S, Kim BK. RANTES Polymorphisms and the Risk of Graft-versus-Host Disease in Human Leukocyte Antigen-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation. *Acta Haematol*. 2013;129(3):137-45
9. **Shin DY**, Kim I. Chronic Lymphocytic Leukemia-Era of Targeted Therapy. *Korean J Med* 2013 Aug;85(2):141-153 (in Korean) (Review)
10. **Shin DY**, Na II, Kim CH, Park S, Baek H, Yang SH. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. *J Thorac Oncol* 2014 Feb;9(2):195-9
11. **Shin DY**, Kim DW, Keam B, Kim TM, Lee SH, Kang CH, Kim YT, Heo DS. The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor. – A retrospective cohort study – *Lung Cancer* 2014 Aug;85(2):320-5
12. **Shin DY**, Kim A, Kang HJ, Park S, Kim DWE, Lee SS. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma. *Cancer Lett*. 2015 Aug 10;364(2):89-97
13. **Shin DY**, Lee HR, Kang HJ, Na II, Chang YH, Yang SH. Prevalent factor XII deficiency in cancer patients with isolated aPTT prolongation. *Blood Res*. 2015 Jun; 50(2):114-7
14. **Shin DY**, Choi YH, Lee HR, Na II, Yuh YJ, Kim BS, Chung IJ, Bae WK, Shim HJ, Song EK, Yang SH, Kang HJ. A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. *Cancer Chemother Pharmacol*. 2016. Jan;77(1):163-8
15. **Shin DY**, Kim A, Byun BH, Moon H, Kim S, Ko YJ, Kim MJ, Lee HR, Kang HJ, Na II, Park S, Lee SS, Yang SH. Visceral adipose tissue is prognostic for survival of diffuse large B-cell

lymphoma treated with frontline R-CHOP. *Ann Hematol.* 2015. Feb;95(3):409-16 (Corresponding author)

16. **Shin DY**, Kim SJ, Yoon DH, Park Y, Kong JH, Kim JA, Kim BS, Kim HJ, Won JH, Park SK, Kim WS. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. *Cancer Chemother Pharmacol.* 2016. Apr;77(4):865-73

17. **Shin DY**, Lee DH, Kim CH, Koh JS, Lee JC, Baek HJ, Kim SW, Choi CM, Na II. Epidermal growth factor receptor mutations and brain metastasis in patients with nonadenocarcinoma of the lung. *J Cancer Res Ther* 2016. Jan-Mar; 12(1): 318-22

18. **Shin DY**, Byun BH, Kim KM, Kang JH, Lim I, Kim BI, Lee SS, Choi CW, Kang HJ, Lim SM. Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. *Cancer Chemother Pharmacol.* 2016. Oct;78(4):825-31

19. Liu Y, **Shin DY**, Oh S, Kim S, Koh Y, Kim I. KML001 and doxercalciferol induce synergistic antileukemic effect in acute lymphoid leukemia cells. *Oncol Rep.* 2017 Jul;38(1):481-487 (Co-1st author)

20. **Shin DY**, Lee JH, Park S, Lee JO, Moon JH, Ahn JS, Choi Y, Song IC, Shin HJ, Lee WD, Lee HS, Yoon SS. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignancies. *Bone Marrow Transplant.* 2018. Feb; 53(2): 207-212

21. **Shin DY**, Park JK, Kim SM, Im K, Kim JA, Kim SY, Hwang SM, Yoon SS, Lee DS. The role of ASXL1 mutation in idiopathic cytopenia of undetermined significance. *Leukemia and Lymphoma* 2019 Mar; 60(3): 756-763

22. **Shin DY**, Park JK, Li CC, Park HS, Moon SY, Kim SM, Im K, Chang YH, Yoon SS, Lee DS. Replicative senescence of hematopoietic cells in patients with idiopathic cytopenia of undetermined significance. *Leuk Res.* 2019 Apr;79:22-26

23. Oh YJ, **Shin DY**, Hwang SM, Kim SM, Im K, Park HS, Kim JA, Song YW, Marquez A, Martin J, Lee DS, Park JK. Mutation of Ten-Eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. *Korean J Intern Med* 2020 Mar; 35(2):457-464 (Co-1st author)

24. Park H, **Shin DY**, Kim I, Sohn SK, Koh Y, Lee JH, Lee KH, Kim DY, Kim HJ, Ahn JS, Lee JO, Bang SM, Cheong JW, Park SG, Park S, Lee YJ, Ahn SY. Use of droplet digital polymerase chain reaction for detecting minimal residual disease: A prospective multi-institutional study. *In vivo.* 2019 Nov-Dec;33(6):2273-2280 (Co-1st author)

25. Choi M, **Shin DY**, Lee JY, Kim I, Yoon SS, Bang SM. Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. *Blood Res.* 2019 Dec; 54(4): 2900-295 (Corresponding author)

26. Choi M, Heo JY, **Shin DY**, Lee JY, Koh Y, Hong J, Kim I, Yoon SS, Lee JO, Bang SM. Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity

conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. *Blood Res.* 2020 Mar;55(1):27-34 (Corresponding author)

27. Han H, **Shin DY**, Kim D, Kim H, Lee C, Koh Y, Hong J, Yoon SS. Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD+ acute myeloid leukemia. *Leuk Lymphoma* 2020 May 6;1-11 (*Co-1st author*)

28. Shin DH, **Shin DY**, Kang CK, Park S, Park J, Jun KI, Kim TS, Koh Y, Hong J, Choe PG, Park WB, Kim NJ, Yoon SS, Kim I, Oh MD. Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia. *BMC Infect Dis.* 2020 Jun 9;20(1):404 (*Co-1st author*)

29. **Shin DY**, Huang X, Gil CH, Aljouji A, Ropa J, Broxmeyer HE. Physioxia enhances T-cell development ex vivo from human hematopoietic stem and progenitor cells. *Stem Cells* 2020 Nov;38(11): 1454-1466.

30. Han H, Byun JM, **Shin DY**, Toon SS, Koh Y, Hong J, Kim I, Yoo H, Yun H, Kim MJ, Cho SI, Seong MW, Park SS. Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia. *Korean J Intern Med.* 2020 Aug 20 [Epub]. (*Corresponding author*)

31. Kim HK, Son SY, Oh JS, Song YN, Byun JM, Koh Y, Hong J, Yoon SS, Lee CH, **Shin DY**, Lee MR. Metabolic profiling during acute myeloid leukemia progression using paired clinical bone marrow serum samples. *Metabolites.* 2021 Aug 31; 11(9): 586 (*Co-corresponding author*)

32. Kim S, **Shin DY**, Kim D, Oh S, Hong J, Kim I, Kim E. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes *Cells.* Dec 10; 10(12): 3494 (*Co-1st author*)

33. Kim D, **Shin DY**, Liu J, Jeong NR, Koh Y, Hong J, Huang X, Broxmeyer H, Yoon SS. Expansion of human megakaryocyte-lineage progeny via aryl hydrocarbon receptor antagonism with CH223191. *Stem Cell Reviews and Reports.* 2022, accepted (*Corresponding author*)